Infasurf

Product manufactured by Ony Biotech Inc.

Application Nr Approved Date Route Status External Links
BLA020521 None Endotracheal None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

Indications And Usage Infasurf Is Indicated For The Prevention Of Respiratory Distress Syndrome (rds) In Premature Infants At High Risk For Rds And For The Treatment (“rescue”) Of Premature Infants Who Develop Rds. Infasurf Decreases The Incidence Of Rds, Mortality Due To Rds, And Air Leaks Associated With Rds. Prophylaxis Prophylaxis Therapy At Birth With Infasurf Is Indicated For Premature Infants Less Than 29 Weeks Of Gestational Age At Significant Risk For Rds. Infasurf Prophylaxis Should Be Administered As Soon As Possible, Preferably Within 30 Minutes After Birth. Treatment Infasurf Therapy Is Indicated For Infants Less Than Or Equal To 72 Hours Of Age With Rds (confirmed By Clinical And Radiologic Findings) And Requiring Endotracheal Intubation.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Calfactant

Comments